Coronavirus epidemic snarls science worldwide

 

 

 

 

The coronavirus epidemic now racing across China is forcing Jeffrey Erlich, a Canadian neuroscientist at New York University Shanghai, to weigh his science against concern for his staff. Erlich performs animal experiments at a neighboring university; as part of efforts to control the illness, known as COVID-19, officials there have asked him to halt the studies and use as few staff as possible to take care of his animals. But he is training mice and other species on very complex tasks; the interruption could set him back 6 to 9 months. “It’s really hard balancing the research productivity of the lab and the safety and comfort of my staff,” he says. “When you’ve invested years of work into experiments, where do you draw the line about what’s considered essential?”

Erlich is just one of thousands of scientists in China whose work is suffering. Universities across the country have been closed since the Lunar New Year, 25 January. Access to labs is restricted, and projects have been mothballed, fieldwork interrupted, and travel severely curtailed. Scientists elsewhere in the world are feeling the impact as well, as collaborations with China are on pause and many scientific meetings, some as far away as June, have been canceled or postponed.

The damage to research pales compared with the human suffering wrought by the virus. As Science went to press, the total number of cases had risen to 73,332, almost 99% of them in China, and 1873 deaths had been counted; the specter of a pandemic is still very real. Still, for individual researchers the losses can be serious—and stressful. “Basically, everything has completely stopped,” says John Speakman, who runs an animal behavior lab at the Chinese Academy of Sciences (CAS) in Beijing. “The disruption is enormous. The stress on the staff is really high.” But Speakman says he understands why the Chinese government closed universities and institutes. “It’s annoying, but I completely support what they have done,” he says.

Disruptions are particularly acute in Wuhan and other cities in Hubei province, the epicenter of the outbreak, which are almost completely cut off from the outside world. “I’m working more now than ever before the epidemic,” says Sara Platto, a professor of animal behavior at Jianghan University in Wuhan. But she faces major obstacles: Faculty and students living on campus are confined to their apartments, and Platto, who lives off-campus, can venture outside only once every 3 days. She is working with colleagues in Beijing who are studying the relationship of the novel virus to another coronavirus isolated from a pangolin. But a paper she is writing has been delayed because her notes are in her office and she can’t get back on campus.

The situation is not much better in other cities. “Unfortunately, the virus is very annoying with regards to work,” says Jingmai O’Connor, a paleontologist at CAS’s Institute for Vertebrate Paleontology in Beijing. “There is no one working the collection, no one to sign paperwork so things can’t get done, overseas travel is canceled. … No samples can be analyzed, all we can do is work on preexisting data on our computers,” O’Connor says. “It sucks!”

Some researchers in China have switched from lab work to writing papers and grant applications. The National Science Foundation of China has postponed grant application deadlines by several weeks, giving researchers time to catch up. Online classes, which many universities and institutes have ramped up to keep students on schedule, are also keeping scientists busy. Poo Muming, a neuroscientist at CAS’s Center for Excellence in Brain Science and Intelligence Technology, says he is teaching daily 2-hour neurobiology lectures: “Surprisingly, there are thousands of people tuning in each day.”

China’s lockdown is felt even half a world away. Daniel Kammen, a renewable energy researcher at the University of California, Berkeley, says it is impeding his lab’s efforts to help set up green transportation projects, including the rollout of electric taxis, throughout China.

But labs working on the fight against COVID-19 are in overdrive. At Tsinghua University in Beijing, Zhang Linqi has switched from HIV to the novel coronavirus; his lab members even decided to forgo the Lunar New Year celebrations last month. “[We] decided we would celebrate it by conducting research,” Zhang says. The team synthesized and characterized the “spike” on the coronavirus’s surface, a protein that helps it enter human cells; Zhang’s lab has joined industrial partners to develop a vaccine targeting the spike. Countless infectious disease labs in the rest of the world have put their regular work on hold as well. “The main effect has been the need to triage work, to push other projects to the back burner while we help our Chinese colleagues analyze the vast amount of new COVID-19 data,” says Christopher Dye of the University of Oxford.

The spread of the virus has upended plans for numerous scientific conferences. So far, more than a dozen have been canceled or postponed—not just in China but elsewhere in Asia and Europe as well. Among the casualties are the International Society for Stem Cell Research’s international symposium, which was scheduled for March in Shanghai, and the 2nd Singapore ECS Symposium on Energy Materials in early April. Organizers of the International Congress on Infectious Diseases, planned for 20–24 February in Kuala Lumpur, Malaysia, postponed their meeting, saying the priority for its registrants is to fight the coronavirus outbreak in their home countries.

Concern is also rising that the epidemic could disrupt the global medicine supply. China and India produce an estimated 80% of all active pharmaceutical ingredients, the raw materials for antibiotics and drugs for cancer, heart disease, and diabetes. With many Chinese factories shuttered, stockpiles could run short. “This is a very acute issue now,” says Michael Osterholm, the head the Center for Infectious Disease Research and Policy at the University of Minnesota, Minneapolis, which studies drug availability.

But Mariângela Simão, assistant director general for access to medicines and health products at the World Health Organization, says the agency sees no “immediate risk” of COVID-19 affecting supplies of essential medicines. Simão’s team is in daily contact with international pharmaceutical associations, which track shipping disruptions from their member companies. Many companies stockpiled 2 to 4 months of their products prior to the Lunar New Year celebrations, she says. And while Hubei is home to some pharmaceutical companies, far more are in Shanghai and other parts of China that are less affected. But the picture could change if the virus isn’t brought under control, Simão notes. “It will all depend on how the situations evolve with the outbreak.”

 

 

 

(원문: 여기를 클릭하세요~)